Financial Performance - In 2023, the company achieved operating revenue of RMB 12,430.04 million, a year-on-year decrease of 1.58%[9] - The net profit attributable to shareholders was RMB 1,953.65 million, representing a year-on-year increase of 2.32%[9] - The proposed profit distribution plan for 2023 includes a cash dividend of RMB 13.50 per 10 shares, subject to approval at the annual general meeting[22] - The company reported a significant increase in revenue, achieving a total of RMB 1.5 billion, representing a year-over-year growth of 20%[37] - The net cash flow from operating activities increased by 17.18% to CNY 3,248,934.19 in 2023[38] - The total assets as of December 31, 2023, were CNY 25,044,827.13, representing a 0.71% increase from the beginning of the year[39] - The total liabilities increased by 3.49% to CNY 10,278,124.13 as of December 31, 2023[39] - The return on equity for 2023 was 14.00%, a decrease of 0.31 percentage points from the previous year[39] - Basic earnings per share for 2023 were CNY 2.10, up 2.94% from CNY 2.04 in 2022[38] Research and Development - The company has made significant progress in R&D, with multiple products including injectable Triptorelin microspheres and Voriconazole approved for market[10] - The company is focusing on high-barrier complex formulations and innovative drugs in fields such as oncology and reproductive health[10] - Over 65% of participants have been enrolled in the Phase III clinical trial for recombinant human follicle-stimulating hormone injection[11] - The company aims to enhance its leading advantages in innovative drugs and high-barrier complex formulations, focusing on areas such as digestive, mental health, reproductive assistance, and anti-tumor fields[15] - The company is committed to enhancing its research and development capabilities, with ongoing projects in various therapeutic areas, which will support long-term growth[104] - The company reported a total R&D investment of approximately RMB 1.24 billion in 2023, a decrease of 11.86% compared to RMB 1.40 billion in 2022[107] - The number of R&D personnel decreased by 6.89% to 906 in 2023, down from 973 in 2022[106] Market Expansion and Strategy - The company has initiated international collaborations and licensing agreements to expand its product pipeline and market reach[13] - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[37] - The company is actively expanding its international business, with ongoing sales and registration efforts in countries like Pakistan, Indonesia, and the Philippines[60] - The company is focusing on unmet clinical needs and investing in innovative drug development to ensure sustainable growth[195] - The company plans to advance the development of traditional Chinese medicine formulations and enhance the marketing of key products in oncology and antiviral sectors[186] Corporate Social Responsibility and Sustainability - The company’s MSCI ESG rating achieved the highest level of AAA, becoming the first Chinese pharmaceutical company to receive this rating[14] - The company is committed to social responsibility, covering 8 provinces and 4 autonomous regions with its chronic disease prevention project[14] - The company has set a goal to achieve carbon neutrality by 2055, emphasizing its commitment to sustainable development and environmental protection[16] - The company is committed to strict compliance with environmental regulations and aims to achieve carbon neutrality by 2055[198] Marketing and Sales - The company is enhancing its marketing strategies through evidence-based and collaborative marketing approaches[12] - The company has strengthened its marketing management and established key product line divisions to enhance customer market share in three major areas[70] - The marketing strategy includes rapid coverage of core products, particularly in the digestive field, and expanding market presence in assisted reproduction and mental health sectors[182] Investment and Financial Management - The company has implemented new strategies focusing on digital marketing, which is expected to improve customer engagement by 30%[37] - The company plans to invest RMB 200 million in upgrading its manufacturing facilities to meet international quality standards[37] - The company has reported a total investment in securities of approximately RMB 236.5 million, with a loss of RMB 24.38 million during the reporting period[155] - The company has established measures to mitigate market risks associated with foreign exchange operations, ensuring that these contracts are not used for speculative trading[159] Investor Relations - The company engaged in multiple investor communications throughout January to July 2023, primarily through phone calls with institutional investors[199] - The investor relations activities were documented and made available on the company's official website, ensuring accessibility of information to stakeholders[199] - The company has maintained transparency in its communications, responding to inquiries based on actual operational conditions[199]

Financial Performance - For the year 2023, the company achieved a revenue of RMB 12,430.04 million, a year-on-year decrease of 1.58%[16] - The net profit attributable to shareholders for 2023 was RMB 1,953.65 million, representing a year-on-year increase of 2.32%[16] - Excluding non-recurring gains and losses, the net profit from core business for 2023 was RMB 1,881.35 million, a slight increase of 0.05% year-on-year[16] - The company reported total operating revenue of RMB 12,430.04 million, representing a year-on-year increase of 2.94%[28] - The net profit attributable to shareholders was RMB 1,744.89 million, reflecting a growth of 14.04% compared to the previous year[29] - The company reported a net profit of RMB 581,909,331.89 thousand in the first quarter of 2023[65] - The company reported a total operating cost of RMB 4,465,473,361.10, a slight increase of 0.09% from RMB 4,461,283,076.09 in 2022[118] - The income tax expense for the year was RMB 485.07 million, an increase of 29.36% year-on-year, primarily due to the company's operating results[129] - The company has made adjustments to previous years' financial data due to changes in accounting policies[58] Dividend and Shareholder Returns - The board proposed a cash dividend of RMB 13.50 per 10 shares (before tax) for the 2023 fiscal year, pending approval at the annual general meeting[17] - The company plans to distribute a cash dividend of RMB 13.50 per 10 shares to all shareholders, pending approval at the 2023 annual general meeting[37] - The dividend distribution is expected to occur on July 8, 2024, for A-share shareholders and August 5, 2024, for H-share shareholders[37] Research and Development - In 2023, the company focused on R&D innovation, particularly in the fields of digestive, mental health, reproductive assistance, and oncology, enhancing its differentiated product pipeline[18] - The company has established a robust R&D innovation system, optimizing management structures across clinical operations and drug safety, leading to accelerated realization of innovative research outcomes[18] - The company aims to enhance R&D efficiency and strengthen its leading position in innovative drugs and complex formulations, focusing on areas such as digestive, mental health, reproductive assistance, and oncology[24] - The company has initiated multiple clinical trials, including a Phase III trial for recombinant human IL-17A/F monoclonal antibody injection and completed enrollment for semaglutide injection for type 2 diabetes[20] - The company has made significant progress in R&D, with the approval of the injection of Triptorelin Acetate microspheres for prostate cancer and the completion of Phase III clinical trials for endometriosis[78] - The company is advancing several R&D projects, including a long-acting implant for prostate cancer and a micro-injection for endometriosis, all in preclinical research stages[137] Market Expansion and Product Development - The company accelerated the internationalization of its products, contributing to a comprehensive enhancement of its long-term sustainable development capabilities[14] - The company introduced innovative drugs in the gastrointestinal and cardiovascular fields, strengthening its international collaboration and licensing efforts[21] - The company has analyzed potential risk factors and response strategies for future development in the management discussion and analysis section of the report[37] - Livzon plans to expand its market presence in Southeast Asia, targeting a 30% increase in sales from this region by 2025[45] - The company is actively pursuing international collaboration and innovation business models to enhance its global market presence[69] - The company is focusing on high-barrier complex formulations and innovative drugs, strengthening its integrated raw material and formulation capabilities[98] Environmental and Social Responsibility - The company achieved an MSCI ESG rating of AAA, becoming the first Chinese pharmaceutical company to receive this highest rating[23] - The company plans to achieve carbon neutrality by 2055 and is committed to increasing environmental protection investments[26] Financial Position and Assets - The total assets as of December 31, 2023, were RMB 25,044,827.13 thousand, reflecting a 0.71% increase from the previous year[59] - The total liabilities increased by 3.49% to RMB 10,278,124.13 thousand as of December 31, 2023[59] - The return on equity attributable to shareholders was 13.91%, an increase of 0.15 percentage points compared to the previous year[59] - The company's asset-liability ratio increased from 39.94% in 2022 to 41.04% in 2023[157] - The total outstanding debt as of December 31, 2023, is RMB 5,014.84 million, an increase from RMB 4,604.43 million as of December 31, 2022, representing an increase of 8.9%[171] Risk Management and Compliance - The company has implemented long-term equity incentive plans to motivate employees and align their growth with the company's development[23] - The company continues to address corruption issues in the pharmaceutical industry through a comprehensive governance approach initiated by the National Health Commission[3] - Forward-looking statements in the report are subject to risks and uncertainties, and actual results may differ significantly from these statements[37] Investment and Financing Activities - The company has made significant equity investments, including RMB 600 million in Wuhan Kangli Health Investment, acquiring a 60% stake, and RMB 102 million in Guangdong Lijian Animal Health, acquiring a 51% stake[183] - The total investment amount for the year reached RMB 729.64 million, a significant increase of 1,724.08% compared to RMB 40.00 million in the previous year[182] - The company has capital commitments totaling RMB 709.93 million, which includes commitments for long-term asset construction and R&D expenditures[168] Product Pipeline and Approvals - The company has successfully launched several new products, including tocilizumab injection and new indications for injectable esomeprazole sodium, enhancing its product pipeline in various therapeutic areas[131] - The company has received emergency use authorization for the recombinant novel coronavirus fusion protein vaccine, which is expected to enrich its vaccine product pipeline[133] - The injectable progesterone solution for women undergoing assisted reproductive technology has been submitted for approval, aiming to expand the company's offerings in the reproductive health sector[133] - The injectable phosphoric acid tedizolid for acute bacterial skin and skin structure infections has been submitted for market approval, which will enhance the company's infection control product pipeline[133]

Financial Performance - The company's operating revenue for Q3 2023 was approximately ¥2.96 billion, a decrease of 6.93% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2023 was approximately ¥481.87 million, an increase of 4.18% year-on-year[4] - For the first nine months of 2023, the total operating revenue reached approximately ¥9.65 billion, reflecting a year-on-year growth of 1.76%[8] - The basic earnings per share for Q3 2023 was ¥0.50, down 3.85% from the previous year[4] - The net profit attributable to shareholders of the parent company was RMB 1,601,554,878.96, representing a year-on-year increase of 6.3% from RMB 1,506,800,118.40[17] - The total comprehensive income for the first nine months was RMB 1,574,273,032.51, compared to RMB 1,660,625,774.20 in the previous year, showing a decline of 5.2%[18] Assets and Liabilities - The company's total assets as of the end of Q3 2023 were approximately ¥24.80 billion, a slight decrease of 0.26% from the end of the previous year[5] - As of the end of Q3 2023, current assets totaled RMB 16,984,391,531.73, slightly down from RMB 16,987,297,040.38 at the beginning of the year[15] - Total liabilities increased to RMB 10,331,726,594.21 from RMB 9,928,573,774.51, marking an increase of about 4.05%[16] - Long-term borrowings rose significantly to RMB 2,428,728,610.19 from RMB 1,974,444,042.88, representing an increase of approximately 22.94%[16] - The company's total equity decreased to RMB 14,468,236,857.29 from RMB 14,936,251,591.72, a decline of about 3.14%[16] - The total liabilities to equity ratio increased, indicating a higher leverage position for the company compared to the previous period[16] Cash Flow and Investments - Investment cash inflow increased significantly to ¥457,840,165.72, up 543.62% from ¥71,135,583.20 in the same period last year, primarily due to the recovery of investment funds[9] - Net cash flow from financing activities decreased to -¥1,768,301,850.08, a decline of 133.41% compared to -¥757,588,971.12 in the previous year, mainly due to reduced new borrowings and payments for share repurchases[9] - The cash flow from operating activities generated a net amount of RMB 2,212,403,355.39, up from RMB 1,847,923,769.75 in the same period last year, indicating a growth of 19.7%[19] - The company's investment activities resulted in a net cash outflow of RMB -553,929,894.90, an improvement from RMB -769,052,038.33 in the same period last year[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 45,778, with the top ten shareholders holding significant stakes, including Hong Kong Central Clearing Limited at 33.09%[11] - The company repurchased a total of 11,614,548 A shares, accounting for 1.24% of the total share capital, with a total expenditure of ¥402,016,931.96[13] - The highest repurchase price was ¥37.34 per share, while the lowest was ¥32.25 per share[13] - The company’s major shareholder, Health元 Pharmaceutical Group, holds 23.66% of the shares, indicating a strong influence on corporate governance[11] Operational Insights - The company reported a significant decrease of 72.23% in contract liabilities, amounting to approximately ¥62.81 million, due to revenue recognition of previously received payments[8] - The company experienced a 55.66% decrease in construction in progress, totaling approximately ¥267.12 million, attributed to the completion of new production lines[8] - The revenue from traditional Chinese medicine products increased by 50.17% year-on-year, reaching approximately ¥1.25 billion in the first nine months of 2023[8] - The company reported a decrease in sales expenses to RMB 2,814,431,433.12, down from RMB 2,902,292,445.97, reflecting a reduction of 3.0%[17] Financial Ratios and Expenses - The weighted average return on equity for the first nine months of 2023 was 11.38%, an increase of 0.04 percentage points year-on-year[4] - Research and development expenses amounted to RMB 985,755,413.94, which is a marginal increase from RMB 978,746,743.57 in the previous year[17] - The financial expenses showed an improvement, with a net financial cost of RMB -216,475,683.51 compared to RMB -254,166,791.47 in the previous year[17] Miscellaneous - The third quarter report of Livzon Pharmaceutical Group Co., Ltd. is unaudited[20] - The report was released on October 25, 2023[20] - No specific financial performance metrics or user data were provided in the report[20] - Future outlook and performance guidance were not detailed in the report[20] - There was no mention of new product or technology development in the report[20] - Market expansion and acquisition strategies were not discussed in the report[20] - Other new strategies were not highlighted in the report[20] - The report does not include any specific revenue or profit figures[20] - No comparative performance data or percentage changes were provided[20] - The report lacks detailed insights into operational performance[20]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 麗 珠醫 藥集 團股 份有 限公 司 LIVZON PHARMACEUTICAL GROUP INC.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：1513） 2023年第三季度報告 麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「公司」或「本公司」，連同其 附屬公司，統稱「本集團」）根據香港聯合交易所有限公司證券上市規則第13.09條和第13.10B 條以及香港法例第571章證券及期貨條例第XIVA部內幕消息條文刊發本公告。 本公司及董事會全體成員保證信息披露的內容真實、準確、完整，沒有虛假記載、誤導性陳 述或重大遺漏。 重要內容提示： 1. 本公司董事會、監事會及董事、監事、高級管理人員保證公司2023年第三季度報告（「本 季度報告」）的真實、準確、完整，不存在虛假記載、誤導性陳述或重大遺漏，並承擔 ...

Financial Performance - Livzon Pharmaceutical reported a revenue of RMB 6,689.92 million for the first half of 2023, representing a 6.15% increase compared to the same period in 2022[15]. - The net profit attributable to shareholders was RMB 1,227.31 million, reflecting a decrease of 13.96% year-over-year[15]. - The basic earnings per share increased by 11.93% to RMB 1.22 compared to RMB 1.09 in the previous year[16]. - Livzon Pharmaceutical's cash flow from operating activities was RMB 1,423.37 million, showing a 6.15% increase from the previous year[15]. - The company achieved operating revenue of RMB 6,689.92 million, a year-on-year increase of 6.15% compared to RMB 6,302.57 million in the same period last year[43]. - Net profit attributable to shareholders reached RMB 1,134.57 million, reflecting an 11.50% increase from RMB 1,017.55 million in the previous year[43]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 1,093.71 million, up 4.52% from RMB 1,046.42 million in the same period last year[43]. - The company reported a total income tax expense of RMB 249.30 million, which is a 21.57% increase year-on-year, primarily due to higher taxable income[76]. Revenue Breakdown - Revenue from chemical preparations reached RMB 3,480.29 million, accounting for 52.02% of total revenue[16]. - The revenue from biological products increased by 14.26% to RMB 953.85 million[16]. - The revenue from traditional Chinese medicine preparations reached RMB 953.85 million, a year-on-year increase of 94.42%, accounting for 14.26% of the total revenue[57]. - The revenue from diagnostic reagents and equipment was RMB 297.99 million, a year-on-year decrease of 13.88%, representing 4.45% of the total revenue[58]. - The revenue from APIs and intermediates was RMB 1,781.67 million, a year-on-year increase of 3.03%, accounting for 26.63% of the total revenue[54]. - The revenue from chemical agents was RMB 3,480.29 million, a year-on-year decrease of 2.42%, accounting for 52.02% of the total revenue[45]. - The revenue from biological products was RMB 113.41 million, a year-on-year increase of 5.93%, accounting for 1.70% of the total revenue[51]. Strategic Initiatives - The company is focusing on new product development and market expansion strategies to enhance growth prospects[18]. - Livzon plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2024[30]. - The company is investing RMB 200 million in R&D for new drug development, focusing on innovative therapies for chronic diseases[30]. - Livzon is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[30]. - The company is actively pursuing international cooperation and licensing for its innovative products and pipelines, with ongoing discussions with multiple international partners[60]. - The company has achieved a strategic partnership with leading global pharmaceutical companies, enhancing its market position[54]. Research and Development - The company has made significant progress in the development of new drugs, including the approval of the injection of leuprolide acetate microspheres for prostate cancer[46]. - The company has registered 20 products in 11 overseas countries/regions as of the end of the reporting period[49]. - The company has completed 135 international registration projects for APIs and intermediates in 63 overseas countries/regions[55]. - The company has nine ongoing research projects in traditional Chinese medicine, with the SXSHL gel completing preclinical studies and the TGDX granules finishing clinical trials[57]. - The company has 7 ongoing research projects for complex formulations, with 1 approved for market and 1 completing Phase III clinical trials[79]. - A total of 27 key projects are under research, with 3 approved for market and 4 in the production application stage[80]. - In the biopharmaceutical sector, there are 8 ongoing projects, with 2 approved for market and 1 approved for emergency use[81]. Market Expansion and Sales - User data indicates a growth in customer base by 25%, with over 5 million active users engaging with the company's products[30]. - The company expects a revenue guidance of RMB 2.5 billion for the full year 2023, reflecting a growth rate of 18%[30]. - The company plans to strengthen its marketing efforts in traditional Chinese medicine, focusing on the sales of specific products like the Qishi Fuzheng injection in oncology and expanding into pediatric and geriatric medicine[182]. - The company aims to improve its supply chain efficiency and strengthen quality management to prevent major quality safety incidents[177]. - The company will continue to focus on the research, production, and sales of pharmaceutical products, including various formulations and active pharmaceutical ingredients[42]. Financial Position and Liabilities - The total assets increased by 3.46% to RMB 25,726.13 million from RMB 24,864.83 million at the beginning of the period[42]. - Total liabilities rose by 15.59% to RMB 11,476.30 million from RMB 9,928.57 million at the beginning of the period[42]. - The asset-liability ratio rose from 39.93% to 44.61% as of June 30, 2023, indicating a higher level of debt relative to assets[94]. - The company's long-term borrowings rose by 32.81% to RMB 2,622,263,438.94, primarily due to new bank loans[92]. - The group’s total borrowings amounted to RMB 4,232.26 million as of June 30, 2023, up from RMB 3,596.68 million as of December 31, 2022, representing 16.45% of total assets[105]. Investment and Capital Expenditure - The company has invested RMB 54,850.66 million in the Sichuan Guangda relocation and expansion project, with government subsidies totaling RMB 17,443.17 million received[120]. - The company plans to invest a total of RMB 20,820.90 million in the new product development and industrial upgrading project, with expected annual investments over the next five years[145]. - The company has committed to using the raised funds for specific projects, including the development of innovative products and technology upgrades, aligning with its strategic goals[141]. - The company has reported a significant increase in investment amounting to RMB 727,085,150.00 for the current period, compared to RMB 30,000,065.77 in the previous period, reflecting a change of 2,323.61%[123]. - The company has allocated RMB 51,685.32 million for replenishing working capital and repaying bank loans, achieving 100% of the planned investment[154]. Risk Management and Compliance - The company has implemented a foreign exchange risk management system to mitigate the impact of currency fluctuations on its business[112]. - The company is actively monitoring industry policy changes and will strengthen its compliance and operational capabilities in response to evolving regulations[185]. - The company has established risk management measures to mitigate market, operational, and legal risks associated with derivative investments[136]. - The company aims to enhance its operational efficiency through improved risk management practices in derivative trading[136]. Sustainability and Environmental Initiatives - The company aims to achieve carbon neutrality by 2055, enhancing its commitment to green and low-carbon operations[195]. - The company has established GAP production bases for key traditional Chinese medicine raw materials to mitigate supply risks[194]. - The company aims to establish a green ecological planting base for key medicinal materials to support its core product research and development[182].

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2023-072 丽珠医药集团股份有限公司关于 注射用醋酸曲普瑞林微球新适应症上市许可申请获受理的公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，丽珠医药集团股份有限公司（以下简称"本公司"）及控股子公司上 海丽珠制药有限公司收到国家药品监督管理局核准签发的《受理通知书》（受理 号：CXHS2300072），受理注射用醋酸曲普瑞林微球子宫内膜异位症注册上市 许可的申请。现将有关详情公告如下： 一、受理通知书主要内容 药品通用名称：注射用醋酸曲普瑞林微球 英文名：Triptorelin Acetate Microspheres for Injection 剂型：注射剂 规格：3.75mg（按 C64H82N18O13计） 申请事项：境内生产药品注册上市许可 注册分类：化学药品 2.4 类 受理通知书审批结论：根据《中华人民共和国行政许可法》第三十二条的规 定，经审查，决定予以受理。 二、药品的相关情况 注射用醋酸曲普瑞林微球是本公司自主开发的高端长效微球制剂，已于2023 年5 ...

Financial Performance - Livzon Pharmaceutical Group reported a revenue increase of 15% year-on-year for the first half of 2023, reaching approximately RMB 1.2 billion[1]. - The company has set a revenue guidance of RMB 2.5 billion for the full year 2023, representing a growth of 12%[1]. - The company reported a significant increase in revenue, achieving a total of RMB 1.5 billion, representing a year-over-year growth of 25%[12]. - The company achieved operating revenue of RMB 6,689.92 million, a year-on-year increase of 6.15% compared to RMB 6,302.57 million in the same period last year[23]. - The company’s revenue from domestic operations was RMB 5,837,038,944.67, which is 87.25% of total revenue, reflecting a year-on-year increase of 7.15%[40]. - Total revenue for the period was RMB 6,689,918,114.87, compared to RMB 6,302,565,210.60 in the previous period, marking an increase of 6.15%[42]. - The company reported a net profit margin of 18% for the first half of 2023, up from 15% in the same period last year[1]. - Net profit attributable to shareholders reached RMB 1,134.57 million, reflecting an 11.50% increase from RMB 1,017.55 million in the previous year[23]. - The company reported a net profit of approximately RMB 393.59 million for the period, with total revenue reaching RMB 1.72 billion, reflecting a strong performance in the pharmaceutical sector[96]. Research and Development - The company plans to invest 10% of its revenue into R&D for new products and technologies in the upcoming fiscal year[1]. - The company is investing in R&D, allocating RMB 200 million for the development of new technologies and products[12]. - R&D expenses amounted to RMB 610,783,249.63, a 10.15% increase from RMB 554,519,983.73 in the previous period[46]. - The company is committed to innovation in drug development, focusing on unmet clinical needs and high-barrier complex formulations, while enhancing its R&D capabilities[111]. - The company is committed to advancing its biopharmaceutical projects, including the clinical trials for key products like recombinant human IL-17A/F monoclonal antibody injection and recombinant human follicle-stimulating hormone injection[104]. Market Expansion - Livzon is focusing on market expansion in Southeast Asia, targeting a 30% increase in market share by the end of 2024[1]. - Market expansion efforts include entering two new international markets, which are projected to generate an additional RMB 500 million in revenue[12]. - The company is focusing on expanding its international market presence, particularly in countries such as Pakistan, Indonesia, and Uzbekistan, for its reproductive, digestive, and antiviral products[24]. - The company is actively exploring partnerships with international firms to enhance its global presence and distribution channels[1]. Product Development - Livzon has launched two new products in the cardiovascular segment, contributing to a 25% increase in sales in that category[1]. - New product launches are expected to contribute an additional RMB 300 million in revenue over the next fiscal year[12]. - The company is focusing on innovative drugs and high-barrier complex formulations, leveraging its unique advantages in raw materials to strengthen the integration of raw materials and formulations[35]. - The company is investing in the development of new traditional Chinese medicine products and classic formulas, aiming to accelerate R&D progress in this area[106]. Financial Management - The company has identified potential risks related to regulatory changes and is developing strategies to mitigate these risks[1]. - The gross margin improved to 45%, up from 40% in the previous year, indicating better cost management[12]. - The total cost of sales for the period was RMB 2,402,469,642.77, up from RMB 2,191,804,060.15, reflecting a growth of 9.62%[42]. - The company’s cash flow from operating activities decreased by 13.96%, amounting to RMB 1,227.31 million compared to RMB 1,426.39 million in the previous period[23]. Employee and Talent Management - The company has developed a talent assessment system to enhance internal talent selection and training, with 23 training programs planned for 2023[76]. - Employee training initiatives have seen high participation and satisfaction rates, aligning with local government initiatives to strengthen the talent pool[77]. - The company has 8,649 employees, a decrease from 9,005 employees as of December 31, 2022[76]. - Total employee compensation for the reporting period was RMB 859.95 million, up from RMB 844.02 million in the previous period, reflecting a year-over-year increase[76]. Environmental and Sustainability Initiatives - The management emphasized a commitment to sustainability, with plans to reduce carbon emissions by 20% over the next three years[12]. - The company aims to achieve carbon neutrality by 2055, enhancing its commitment to green and low-carbon operations[113]. - The company has faced increasing environmental compliance costs due to stricter regulations, necessitating further investment in environmental protection measures[113]. - The company has maintained a zero exceedance record for pollutant emissions, adhering to the standards set by Jiangyin wastewater treatment plant[198]. Corporate Governance - The company has adhered to the Corporate Governance Code from January 1, 2023, to June 30, 2023, in compliance with the Hong Kong Listing Rules[186]. - The board consists of 11 members, including 2 executive directors, 4 non-executive directors, and 5 independent non-executive directors[183]. - The company held a temporary shareholders' meeting on January 10, 2023, with a participation rate of 7.01% to approve the establishment of a joint venture with the controlling shareholder[184]. Strategic Investments - The company is considering strategic acquisitions to enhance its market position, with a budget of up to RMB 1 billion for potential targets[12]. - The company made significant equity investments, including RMB 600 million for a 60% stake in Wuhan Kanglijian Health Investment Management Co., and RMB 102 million for a 51% stake in Lijian (Guangdong) Animal Health Co.[80]. - The company has approved the continuation of the "Lijuzhou Group New Beijiang Pharmaceutical Co., Ltd. relocation and expansion project (Phase I)" after re-evaluating the project that had been on hold for over a year[119].

Financial Performance - The company's operating revenue for the six months ended June 30, 2023, was RMB 6,689.92 million, representing a 6.15% increase compared to the same period last year[15]. - The net profit attributable to shareholders for the same period was RMB 1,227.31 million, reflecting a decrease of 13.96% year-on-year[15]. - The basic earnings per share increased by 11.93% to RMB 1.22 compared to the previous period[16]. - The company reported a net cash flow from operating activities of RMB 1,046.42 million, which is a 4.52% increase from the previous year[15]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2023, representing a 15% year-over-year growth[30]. - The company achieved operating revenue of RMB 6,689.92 million in the first half of 2023, a year-on-year increase of 6.15% compared to RMB 6,302.57 million in the same period last year[43]. - The net profit attributable to shareholders reached RMB 1,134.57 million, reflecting a year-on-year growth of 11.50% from RMB 1,017.55 million[43]. Revenue Breakdown - Revenue from chemical preparations reached RMB 3,480.29 million, accounting for 52.02% of total revenue, with a growth of 26.63%[16]. - The revenue from biological products was RMB 1,781.67 million, showing a growth of 14.26% year-on-year[16]. - The revenue from the raw materials and intermediates segment reached RMB 1,781.67 million, a year-on-year increase of 3.03%, accounting for 26.63% of the total revenue[54]. - The revenue from the Chinese medicine preparation segment reported revenue of RMB 953.85 million, a significant year-on-year growth of 94.42%, representing 14.26% of the total revenue[57]. - The revenue from diagnostic reagents and equipment decreased to RMB 297.99 million, a decline of 13.88%, making up 4.45% of the total revenue[58]. Market Expansion and Strategy - The company is focusing on expanding its market presence and enhancing its product offerings[18]. - Market expansion plans include entering two new international markets by Q4 2023, aiming for a 5% market share in each[30]. - The company actively expanded its international market presence, focusing on product registration in countries such as Pakistan, Indonesia, and Uzbekistan, with 20 product specifications registered in 11 overseas countries/regions[49]. - The company is considering strategic acquisitions to enhance its product portfolio, with a target of completing at least one acquisition by the end of the fiscal year[30]. Research and Development - The company is investing heavily in R&D, with a budget increase of 25% for new drug development initiatives[30]. - The company is enhancing its R&D capabilities and international collaboration to strengthen its competitive edge in various therapeutic areas[63]. - The company is focusing on innovative drugs and high-barrier complex formulations, leveraging its unique advantages in raw materials and formulations integration[64]. - The company is advancing key projects in the field of biological products, including the approval of the recombinant human chorionic gonadotropin injection for overseas registration in Tajikistan and ongoing submissions in other countries[51]. Operational Efficiency - The gross margin improved to 45%, up from 42% in the previous year, reflecting better cost management[30]. - The company has implemented new technologies in production, resulting in a 30% increase in efficiency[30]. - The company is enhancing its production and quality management systems to improve product delivery capabilities and reduce operational costs through lean production initiatives[48]. - The company has implemented measures to improve operational efficiency and safety awareness among employees through training programs[61]. Financial Position and Liabilities - Total assets at the end of the period were RMB 25,726,127,198.95, representing a 3.46% increase from RMB 24,864,825,366.23 at the beginning of the period[36]. - Total liabilities increased by 15.59%, reaching RMB 11,476,301,953.22 compared to RMB 9,928,573,774.51 at the beginning of the period[36]. - The company's asset-liability ratio rose from 39.93% as of December 31, 2022, to 44.61% as of June 30, 2023[94]. - Long-term borrowings increased by 32.81% to RMB 2,622,263,438.94, attributed to new bank loans[93]. Investment and Capital Expenditure - The company has invested RMB 54,850.66 million in the Sichuan Guangda relocation and expansion project, with government subsidies totaling RMB 17,443.17 million received[120]. - The company made significant investments totaling RMB 727,085,150.00 during the reporting period, a 2,323.61% increase compared to the previous period's investment of RMB 30,000,065.77[123]. - The company plans to invest a total of RMB 20,820.90 million in the new product development and industrial upgrading project, with an expected completion date by December 31, 2020[145]. - The company has committed to using the raised funds for various projects, including the development of innovative products and technology platforms, in line with its strategic goals[141]. Compliance and Risk Management - The company has established risk control measures to mitigate market, operational, and legal risks associated with derivatives trading[136]. - The company emphasizes the importance of regulatory compliance and environmental management, increasing investments in environmental protection equipment[195]. - The company is actively monitoring industry policy changes and will strengthen its compliance and operational systems in response to evolving regulations[186]. Future Outlook - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 10% to 12%[30]. - The company plans to enhance its R&D efficiency and strengthen its innovative drug and complex formulation platforms in the second half of 2023[176]. - The company aims to deepen its market presence in key disease areas such as autoimmune diseases and respiratory infections through targeted sales management[183].

Financial Performance - In 2022, Livzon Pharmaceutical Group achieved a revenue of RMB 12,629.58 million, representing a year-on-year growth of 4.69%[8] - The net profit attributable to shareholders for 2022 was RMB 1,909.39 million, an increase of 7.53% compared to the previous year[8] - Excluding non-recurring gains and losses, the net profit attributable to shareholders from core operations was RMB 1,880.46 million, reflecting a growth of 15.57% year-on-year[8] - The company reported a total revenue of RMB 12,629.58 million for the year, representing a 4.69% increase compared to the previous year[16] - The net profit attributable to shareholders was RMB 1,909.39 million, reflecting a growth of 7.53% year-on-year[16] - The company achieved a 15.57% increase in cash flow from operating activities, amounting to RMB 2,772.67 million[16] - The basic earnings per share for 2022 was RMB 2.04, a 7.37% increase from RMB 1.90 in 2021[42] - The total amount of public welfare donations made by the company during the reporting period was approximately RMB 9.98 million[12] Business Development and Strategy - Livzon is focusing on innovative drug development in areas such as digestive, mental health, reproductive assistance, and oncology, with a differentiated product pipeline covering the entire R&D cycle[11] - The company aims to strengthen its competitive advantage through digital transformation and improved operational management[7] - Livzon is actively pursuing business development opportunities, including potential mergers and acquisitions to enhance its product portfolio and market presence[31] - The company has expanded its market channels and established an internet digital marketing platform to increase product penetration in the OTC retail market[12] - The company is committed to enhancing its R&D pipeline, particularly in high-barrier complex formulations and innovative drugs, to meet evolving market demands[49] - The company is focusing on enhancing its product competitiveness through digital transformation and improving operational efficiency[57] Research and Development - Livzon has established a Clinical Research Management Center to optimize the management structure of its medical, clinical operations, and registration teams[11] - The company completed the Phase III clinical trial for the Semaglutide injection and submitted supplementary materials for the prostate cancer indication of Triptorelin microspheres[12] - The company has 86 ongoing R&D projects as of the end of 2022, with 1 project in the clinical evaluation stage[106] - The company has made significant progress in the research and development of complex formulations and new drugs in oncology, reproductive health, and autoimmune diseases[61] - The company is focusing on the development of new traditional Chinese medicine projects, with eight new drug research projects currently underway[72] Market Expansion - Livzon's market expansion efforts have led to a 20% increase in user data, with a growing customer base in both domestic and international markets[31] - The company is actively expanding its international business, particularly in markets such as Pakistan, Indonesia, and Uzbekistan[60] - The company has successfully registered 5 chemical preparation products in overseas markets and submitted 6 new registrations as of December 31, 2022[63] - The company is advancing the conditional listing application for its recombinant COVID-19 vaccine, which has been included in the national immunization program and is now used in over 20 provinces[64] Corporate Governance and Social Responsibility - The board proposed a cash dividend of RMB 16.00 per 10 shares for the 2022 fiscal year, pending approval at the annual general meeting[10] - The company is committed to social responsibility by providing precise assistance to chronic and rare disease patients, contributing to health initiatives in rural areas[15] - The company has established a foreign exchange risk management system to mitigate exposure from non-RMB transactions[147] Financial Position and Assets - Total assets as of December 31, 2022, reached RMB 24,864.83 million, an increase of 11.14% from RMB 22,371.92 million at the end of 2021[42] - The company reported a total of 935,552,687 shares outstanding as of the last trading day before disclosure[44] - The company's total assets increased from RMB 22,366,000,000.00 at the end of 2021 to RMB 24,900,000,000.00 at the end of 2022, reflecting a growth of approximately 11.3%[114] - Cash and cash equivalents rose to RMB 10,411,348,410.09, accounting for 41.87% of total assets, up from 40.88% in the previous year[114] Investment and Financial Management - The company has capital commitments of approximately RMB 406.79 million as of December 31, 2022, down from RMB 886.35 million at the end of 2021[142] - The investment amount for the year was RMB 40,000,152.05, representing a significant decrease of 95.49% compared to RMB 886,650,000.00 in the previous year[154] - The company received government subsidies totaling RMB 13,843.17 million for the Sichuan Guangda relocation and expansion project[151] - The financial performance indicates a need for improved management of investment risks, as evidenced by the reported losses[158] Risk Management - The report includes an analysis of potential risks and response strategies for future development[19] - Forward-looking statements in the report are subject to risks and uncertainties, and actual results may differ significantly from these statements[19] - The company emphasizes the importance of not relying on or using such information improperly, as it may lead to investment risks[19]

Financial Performance - The company's revenue for Q1 2023 was RMB 3,413,055,191.98, a decrease of 1.90% compared to RMB 3,479,027,465.92 in the same period last year[4] - Net profit attributable to shareholders was RMB 581,909,331.89, representing an increase of 5.17% from RMB 553,293,797.77 year-on-year[4] - Basic and diluted earnings per share increased by 5.08% to RMB 0.62, compared to RMB 0.59 in the same period last year[4] - The company reported a total comprehensive income of RMB 547.85 million, down 8.2% from RMB 596.68 million in the previous year[17] - The gross profit margin for the quarter was approximately 63.1%, compared to 66.1% in the same quarter last year[17] - The company’s financial expenses showed a significant improvement, with a net financial income of RMB 8.75 million compared to a loss of RMB 37.93 million in Q1 2022[17] Cash Flow - The net cash flow from operating activities decreased by 57.80% to RMB 299,784,593.85, down from RMB 710,308,938.96 in the previous year[4] - The net cash flow from operating activities was RMB 299.78 million, a significant decrease of 57.8% compared to RMB 710.31 million in Q1 2022[18] - Cash inflows from financing activities decreased by 36.98% to RMB 1,070,315,870.74, mainly due to a reduction in borrowings compared to the previous period[9] - Cash outflows from financing activities decreased by 43.97% to RMB 753,630,238.36, primarily due to lower loan repayments[9] - The net increase in cash and cash equivalents decreased by 36.83% to RMB 527,826,015.13, mainly due to increased raw material procurement costs affecting daily operational cash flow[9] Assets and Liabilities - Total assets at the end of the reporting period were RMB 25,620,821,364.99, an increase of 3.04% from RMB 24,864,825,366.23 at the end of the previous year[4] - Total current assets increased to RMB 17,868,009,401.34 from RMB 16,987,297,040.38, representing a growth of approximately 5.17%[15] - Total liabilities increased to RMB 10,204,667,286.46 from RMB 9,928,573,774.51, marking an increase of about 2.78%[16] - Short-term borrowings rose to RMB 1,800,000,000.00 from RMB 1,622,239,859.89, an increase of approximately 11.00%[16] - Long-term borrowings increased to RMB 2,225,976,993.70 from RMB 1,974,444,042.88, representing a growth of about 12.74%[16] Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders was 56,429, with the largest shareholder holding 33.09% of the shares[10] - The company repurchased a total of 5,232,048 A shares, accounting for 0.56% of the total share capital, with a total expenditure of RMB 177,765,444.64[13] - The highest and lowest prices for the repurchased shares were RMB 35.50 and RMB 32.25 per share, respectively[13] Research and Development - Research and development expenses amounted to RMB 311.41 million, up 8.0% from RMB 288.33 million in Q1 2022[17] - The company reported a significant decrease in development expenses by 53.43% to RMB 125,253,323.41, primarily due to the approval of a new product[7] Government Subsidies - The company reported a total of RMB 40,295,342.15 in government subsidies recognized in the current period[5] Inventory and Cash Equivalents - Cash and cash equivalents rose to RMB 10,868,918,125.10, up from RMB 10,411,348,410.09, an increase of about 4.39%[15] - Inventory increased to RMB 2,238,022,180.23 from RMB 2,045,341,552.12, reflecting a growth of approximately 9.4%[15] - The company's cash and cash equivalents accounted for approximately 60.8% of total current assets[15] Financial Liabilities - The company experienced a 478.94% increase in trading financial liabilities, reaching RMB 4,110,695.40, mainly due to changes in forward foreign exchange contracts[7] Exchange Rate Impact - The impact of exchange rate changes on cash and cash equivalents worsened by 147.55%, resulting in a loss of RMB 23,818,029.01 from foreign currency holdings[9] Audit Information - The company did not conduct an audit for the Q1 2023 report[19]